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The clinical and biological dilemma of preleukemia presenting as aplastic anemia with chromosomal translocation t(4;11) TO 
THE EDITOR
The complex molecular events obligatory for initiation, latency and progression of malignancies is a subject of major research. Although nonrandom chromosomal translocations as well as other aberrations are considered to be of vast importance in the pathogenesis and diagnosis of malignancies, it seems that the exact role played by these molecular events is sometimes not clearly defined. Some chromosomal translocations such as t(14;18), t(2;5), and t(9;22) are typical for hematological malignancies but are also found in normal individuals. Other translocations, such as t(2;5), (8;14) , (14;18) are not specific to a certain malignancy. 1 There are no solid data regarding the occurrence of t(4;11) in normal individuals or in another malignancy than acute lymphatic leukemia.
We describe a patient who presented with pancytopenia after EBV infection with a consistent cytogenetic finding of translocation t(4;11) in recurrent bone marrow aspirations until he ultimately developed full blown acute leukemia 9 months later.
The fact that no other disease apart from ALL is associated with the t(4;11), and that there is no solid basis for its occurrence under normal circumstances, makes the handling of a patient presenting with this translocation prior to a diagnosis of ALL more complicated.
The patient is a 7-year-old boy of mixed ancestry. His past medical history and history of malignancy in his family were unremarkable. Two months prior to admission to our institute, he was diagnosed as having EBV infection due to clinical and laboratory (including blood smear) results consistent with infectious mononucleosis, and two consecutive serology tests, which were positive for EBV-IgM.
His blood counts rapidly declined and he developed pancytopenia, which persisted for 2 months. At that time, he was referred to our institution for further investigation. On physical examination there was no lymphadenopathy or hepatosplenomegaly. His blood count revealed white blood cells (WBC) 3 × 10 9 /l, absolute neutrophil count (ANC) O.5 × 10 9 /l, Hg 9.1 g/dl, platelet count 141 × 10 9 /l. Bone marrow aspiration showed low cellularity without dysplastic features. Cytogenetic studies showed the translocation t(4;11) in two out of 20 mitoses. Another bone marrow aspiration performed 1 month later revealed the same findings except for cytogenetics, which were not available. A month later (2 months from the first examination), due to lack of improvement in his CBC, a bone marrow biopsy was performed, which showed a recuperative picture with variable marrow cellularity with some patches of fibrosis, but contained hematopoietic precursors at all maturational stages. Cytogenetic studies still showed the t(4;11) and the immunophenotype was normal (Table 1) . During the next 2 months, the patient's CBC gradually normalized. However, 9 months from the initial diagnosis of pancytopenia, he presented with polyarthritis and fever. Aspiration from his bone marrow showed packed marrow (M3) with immunophenotype of pre-B ALL, and the same t(4;11). The patient was treated according to the BFM-high risk protocol and is currently in complete remission 21 months from diagnosis.
Aplastic anemia is a rare syndrome of childhood acute lymphatic leukemia. In a meta-analysis of several large series 2 3% of children with aplastic anemia developed leukemia, and 1.5% of those with ALL began with a hypoplastic phase. The average interval from aplasia to the diagnosis of the disease was 7 months, where only 12% of the patients had an interval of greater than 1 year. Bone marrow karyotypes, which were performed in early stages of the disease, were almost always normal. We describe, for the first time, a patient whose aplastic clone, which later turned out to be malignant, was characterized by the translocation t(4;11) throughout. The chromosomal translocation t(4;11)(q21,23) is present in more than 60% of infants, 2% of children and 3-6% of adults with ALL. It is also known to be associated with secondary leukemias after treatment with topoisomerase 2 inhibitors. This translocation results in fusion of the MLL gene on chromosome 11 and the AF4 gene on chromosome 4. These genes encode proteins that contain regions involved in binding domains of DNA responsible for transcription activation and repression. Therefore, it is believed that the translocation between MLL and AF4, which disrupts these functional activities, may alter the expression of proteins regulated by these genes. The leukemogenic role played by MLL-AF4 was supported by Ford and others 3 in their studies on identical twins with leukemia who shared the same translocation t(4,11), most probably due to the passage of leukemic cells through the placenta. Furthermore, recent data suggest that leukemic blasts bearing the t(4,11) are resistant to CD95-mediated cell death, and fail to be sensitized by gamma interferon. This and other evidence implies that the t(4;11) probably participates actively in leukemogenesis.
Nevertheless, Cimino et al 4 found additional genetic changes in 40% of cases with the t(4;11). Reichel et al 5 performed detailed analyses of the translocation which revealed multiple breakpoints and that DNA fragments had been deleted, inverted or duplicated during the translocation process. These findings strengthen the hypothesis that damage to the DNA repair machinery may be the initial insult in these cases to be followed later by the translocation t(4,11).
Animal studies strengthen these notions. The crucial role of MLL in mammalian development was shown in the disruption of 11q23 in transgenic mice. 6 (MLL +/− animals exhibited retarded growth and hematological abnormalities, MLL −/− was lethal to embryonic development.) These disruptions, however, failed to cause leukemia. Other animal models bearing fused genes known to be associated with leukemia such as CBF␤-Myh11 (inv16) did not develop spontaneous tumors unless they were treated with nitrosourea. These findings suggest that the translocation t(4;11) is a necessary but not sufficient event in the initiation of leukemia.
Only one abstract deals with the occurrence of the MLL-AF4 transcript in normal individuals. Uckun et al 7 detected MLL-AF4 fusion transcripts in up to 25% of fetal liver and bone marrow samples. Although still debatable, these findings suggest that this translocation may be a common occurrence in utero. No data exist, however, regarding the occurrence of the translocation t(4;11) in older, healthy children or adults who never developed leukemia.
The time elapsing between the initial pathological event and the clinical disease has also been a subject of intense studies. The finding that the translocation t(4;11) is present in most infants under 6 months of age with ALL lead scientists to the conclusion that the time between the event and the diagnosis of leukemia must be short. However, Greaves and others have recently shown by using neonatal guthrie cards that leukemia can be traced back to birth. 8 They found evidence for MLL-AF4 and TEL-AML1 fusion genes in neonatal blood spots from children 2 to 4 years of age at the time of diagnosis of leukemia. Other investigators used the same principle and detected T cell and immunoglobulin gene rearrangements in children up to 4 years and 8 months of age upon the diagnosis of leukemia. This information implies that our patient's translocation may exist a long time prior to the sequelae mentioned above.
To summarize, based on the information known today, we believe that one cannot attribute translocation t(4;11) as the only genetic aberration responsible for this child's leukemia. Furthermore, this event may precede leukemia by years. Although it seems reasonable to hypothesize that the second, or last hit may possibly be due to EBV infection. 9 The lack of documentation of this specific translocation prior to the patient's clinical presentation, prevents a more definite approval to this theory. As Greaves and Knudson hypothesized earlier, 9, 10 this case may demonstrate the notion that an array of molecular events within the cell are the determinants of the initiation, latency and progression of leukemia.
As for the practical question of when to intervene when such a translocation is found in an aplastic child, we believe that more studies of preleukemic states in children are needed before such a decision can be made. 
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